A new therapy targeting a common genetic form of high cholesterol has shown promising results in a late-stage clinical trial. The BROOKLYN study, focused on patients with heterozygous familial hypercholesterolemia (HFH), demonstrated that the investigational drug obicetrapib significantly reduced LDL-C, often referred to as “bad” cholesterol, when added to standard statin treatment. This represents a potential advancement for individuals who don’t achieve adequate cholesterol control with existing therapies.
Heterozygous familial hypercholesterolemia is a prevalent genetic condition affecting an estimated 1 in 250 people worldwide, predisposing them to significantly elevated cholesterol levels and an increased risk of early-onset cardiovascular disease. Current treatments, primarily statins, are effective for many, but a substantial portion of patients require additional interventions to reach recommended cholesterol targets. Obicetrapib, developed by NewAmsterdam Pharma, works by inhibiting the protein PCSK9, which regulates LDL-C levels. This mechanism allows the liver to remove more LDL-C from the bloodstream.
The BROOKLYN trial, a randomized, double-blind, placebo-controlled study, involved over 1,000 participants with HFH already taking statin therapy. Results presented earlier this year showed that adding obicetrapib led to a substantial reduction in LDL-C levels, exceeding expectations. Specifically, the drug reduced LDL-C by 55% compared to placebo, bringing many patients into the recommended target range. The findings were presented at the American Heart Association Scientific Sessions in November 2025 and have generated considerable interest within the cardiology community. The full data set is currently under review by regulatory agencies.
Understanding the BROOKLYN Trial Results
The BROOKLYN trial’s success hinges on its rigorous design and the clear demonstration of obicetrapib’s efficacy. Participants were carefully selected based on their genetic confirmation of HFH and their existing statin treatment. The double-blind nature of the study ensured that neither the patients nor the researchers knew who was receiving the active drug or the placebo, minimizing bias. The primary endpoint of the trial was the percentage reduction in LDL-C from baseline to week 24. Secondary endpoints included changes in other lipid parameters, such as HDL-C (“good” cholesterol) and triglycerides.
Although the primary focus was on LDL-C reduction, the trial also assessed the safety and tolerability of obicetrapib. The drug was generally well-tolerated, with most adverse events being mild and comparable to those observed with placebo. Although, as with any medication, potential side effects are being carefully monitored as the drug progresses through the regulatory process. Detailed safety data will be crucial for informing clinical practice and patient management.
The Complex Landscape of Cholesterol Management
Obicetrapib enters a competitive landscape of cholesterol-lowering therapies. Statins remain the cornerstone of treatment, but other options, such as ezetimibe and PCSK9 inhibitors (alirocumab and evolocumab), are available for patients who need additional LDL-C reduction. PCSK9 inhibitors, while highly effective, are typically administered via injection, which can be a barrier for some patients. Obicetrapib is an oral medication, potentially offering a more convenient administration route. The potential for oral administration could significantly improve patient adherence and broaden access to this type of therapy.
The development of obicetrapib also reflects a growing understanding of the genetic basis of hypercholesterolemia. Identifying individuals with HFH through genetic testing allows for targeted interventions and personalized treatment strategies. Early diagnosis and treatment are crucial for preventing the long-term cardiovascular complications associated with this condition. The American Heart Association recommends genetic testing for individuals with premature coronary artery disease or significantly elevated cholesterol levels despite lifestyle modifications and statin therapy.
Financial Implications and Industry Partnerships
NewAmsterdam Pharma has been actively forging partnerships to support the development and commercialization of obicetrapib. In January 2026, the company announced a $950 million deal with Eli Lilly to further advance the drug’s clinical development and prepare for potential market launch. This collaboration highlights the significant interest in novel cholesterol-lowering therapies and the potential for obicetrapib to develop into a major player in the cardiovascular space.
The financial implications of reducing cardiovascular disease burden are substantial. Heart disease remains a leading cause of death and disability worldwide, incurring significant healthcare costs. Effective cholesterol management strategies, like those offered by obicetrapib, have the potential to reduce these costs and improve public health outcomes. However, the ultimate cost-effectiveness of the drug will depend on its pricing and reimbursement policies.
What’s Next for Obicetrapib?
NewAmsterdam Pharma is currently preparing to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for obicetrapib. The FDA will review the data from the BROOKLYN trial and other supporting studies to determine whether the drug is safe and effective for the treatment of HFH. A decision is anticipated in the first half of 2027. The company is also planning to initiate additional clinical trials to evaluate the drug’s potential in other patient populations, such as those with atherosclerotic cardiovascular disease.
The ongoing research and development efforts surrounding obicetrapib underscore the continued need for innovative approaches to cholesterol management. As our understanding of the genetic and molecular mechanisms underlying hypercholesterolemia evolves, we can expect to see even more targeted and effective therapies emerge in the future. The potential approval of obicetrapib would provide clinicians with another valuable tool for combating this widespread and often silent threat to cardiovascular health.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this new cholesterol therapy? Share your comments below, and please share this article with your network.
